Findex and Crowe Horwath are pleased to share a recent transaction delivered for Mundipharma.
Mundipharma Pty Limited has acquired Tolmar Australia Pty Limited, which is a company specialising in medicines and support for men in the advanced stages of prostate cancer. Crowe Horwath advised Mundipharma during the financial due diligence stage of this acquisition process.
The acquisition of Tolmar strengthens Mundipharma’s oncology portfolio, and also includes the exclusive distribution rights for the oncology medication Eligard® injection (leuprorelin acetate) in Australia and New Zealand.
Congratulations to Rahavan Yoganathan (Partner – Corporate Finance), and William McCullough (Manager – Corporate Finance) for their fantastic work on this transaction.
“Crowe Horwath would like to thank Professor Charbert for his insights in assisting the due diligence team in its understanding of the oncology market and the market position and application of the Tolmar portfolio,” said Rahavan Yoganathan.
Crowe Horwath has extensive experience in the health and medical sector, most recently completing significant work for LifeHealthCare and Allegra Group.
To support our work in this sector, Findex (Crowe Horwath’s parent company) is hosting a Business Leaders Forum on March 14, 2018. This exclusive event will bring together more than 50 Private Equity and management level attendees, with a heavy focus on figures from the healthcare industry.
The event will feature guest speaker Professor Ian Frazer. Professor Frazer is a scientist and clinical immunologist from the University of Queensland, and he is also the founding CEO and Director of Research at the Translational Research Institute. The work of Professor Frazer and his late colleague, molecular virologist Dr Jian Zhou, has led to the development of a vaccine which prevents infection with HPV and cervical cancer. Professor Frazer won the 2005 CSIRO Eureka Prize for Leadership in Science, the Australian of the Year in 2006, and the Prime Minister’s Prize for Science in 2008.
At the Business Leader’s Forum, Professor Frazer will discuss innovation in the healthcare sector and the importance of funding innovation in this area.
“Peter Gardiner and the Findex team have previously provided sponsorship support to the Australian Academy of Medicine, and I’m looking forward to sharing my views with the Findex team and their clients,” said Professor Frazer.
“We are again delighted to have Ian join us and share his views around the need for funding of innovation in the health sector. Through our accounting practice Crowe Horwath, we have a growing portfolio of health-related businesses and are actively involved in sourcing the global capital markets to support the sector,” said Peter Gardiner, Executive Managing Partner at Findex.
Findex is very proud to be involved in building connections and supporting innovation within the health sector, as well as hosting key industry figures at events such as the Findex Business Leaders Forum.